Clinical Research Directory
Browse clinical research sites, groups, and studies.
RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Summary
This study is a prospective, open-label, phase II clinical trial that aims to enroll patients with locally advanced gastric adenocarcinoma who have not received any prior treatment and are candidates for surgery. The study drugs include RC48, Adebrelimab, Apatinib and S-1. The purpose is to evaluate the effectiveness and safety of the combined coordinated treatment of multi-mechanism drugs for perioperative treatment of locally advanced gastric cancer with HER2 overexpression.
Official title: Disitamab Vedotin Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer With HER2 Overexpression: a Prospective, Phase II Study
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2024-05-01
Completion Date
2028-05-01
Last Updated
2024-05-13
Healthy Volunteers
No
Interventions
RC48
RC48: 2.5 mg/kg, intravenous infusion, on day 1, every 3 weeks (Q3W);
Adebrelimab
Adebrelimab：1200 mg, intravenous infusion, on day 1, every 3 weeks (Q3W);
Apatinib
Apatinib: 250mg, oral administration, once daily (qd), every 3 weeks (Q3W);
S-1
S-1：For patients with a body surface area (BSA) ≤1.5m², use 50mg each time; for patients with BSA \>1.5m², use 60mg each time, oral administration, twice daily (bid), on days 1-14, every 3 weeks (Q3W);